A novel star-shaped trinuclear platinum(<scp>ii</scp>) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism

Wu, Yixuan; Zhao, Dandan; Shang, Jinting; Huang, Wenxin; Chen, Zhanfen

doi:10.1039/d2dt00895e

Cited by 6 publications

(5 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure 3, when P-235 and P-239 were applied to human breast cancer cells for 48 h, green fluorescence appeared in the mitochondria of them, whereas in the mitochondria of control cells, red fluorescence was visible. This is similar to the reported effect of platinum (II) compounds, indicating that P-235 and P-239 can effectively the depolarization of mitochondrial membrane potential 25 and cause MDA-MB-231 cells to undergo apoptosis. In addition, the green fluorescence intensity of mitochondria of MDA- MB-231 cells treated with P-235 and P-239 was significantly higher than that of cisplatin, whereas the red fluorescence intensity was lower than that of cisplatin, with a better effect than cisplatin.…”

Section: P-235 and P-239 Cause Mitochondrial Membrane Potential Depol...supporting

confidence: 87%

Two novel silver(I) phenanthroline derivative complexes induce G2/M phase cycle arrest and apoptosis of MDA‐MB‐231 cancer cells by multiple mechanisms

Niu

et al. 2023

Applied Organom Chemis

View full text Add to dashboard Cite

Two novel silver(I) phenanthroline derivative complexes (P-235 and P-239) have been synthesized and characterized by IR, HPLC-MS, and 1 HNMR. The cytotoxicity of two complexes exhibited significant cytotoxicity against human breast cancer (MDA-MB-231) cell line (IC 50 = 0.48 ± 0.01 and 0.12 ± 0.01 μM) and less toxicity than cisplatin by MTT assays. Furthermore, anticancer mechanistic studies showed that P-235 and P-239 induced G2/M phase cell cycle arrest to inhibit the growth of MDA-MB-231 cells. Flow cytometry analysis showed that MDA-MB-231 cells could be significantly induced to undergo apoptosis by P-235 and P-239. And P-235-and P-239-induced apoptosis was linked with reactive oxygen species (ROS) production. Further study revealed that P-235 and P-239 cause mitochondrial membrane potential depolarization and destroy mitochondrial membrane potential.

show abstract

Section: P-235 and P-239 Cause Mitochondrial Membrane Potential Depol...supporting

confidence: 87%

Two novel silver(I) phenanthroline derivative complexes induce G2/M phase cycle arrest and apoptosis of MDA‐MB‐231 cancer cells by multiple mechanisms

Niu

et al. 2023

Applied Organom Chemis

View full text Add to dashboard Cite

show abstract

“…A larger proportion of younger women is reported with TNBC than older patients [ 3 , 4 ]. The incidence of breast cancer in young women has increased worldwide in recent years [ 5 ]. In the United States, about 11% of breast cancer patients are between the age of 35 and 45 years, and in Asia are 9.5–12%.…”

Section: Introductionmentioning

confidence: 99%

Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor

Han

Yang

Lü³

et al. 2022

Cancer Cell Int

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor prognosis, early recurrence, and the lack of durable chemotherapy responses and specific targeted treatments. In this preclinical study, we examines Tiliroside (TS, C30H26O13), as one of the major compounds of Tribulus terrestris L. which has been used as an alternative therapy in clinic practice of breast cancer treatment, for its therapeutic use in TNBC. The association between CAXII expression level and survival probability of TNBC patients, and the difference of CAXII expression level between TNBC and normal samples were evaluated by using publicly accessible databases. To determine the anticancer efficacy of TS on TNBC cells, cell proliferation, wound healing, cell invasion, and 3D spheroid formation assays were performed and excellent anticancer activities of TS were displayed. Mouse models further demonstrated that TS significantly reduced the tumor burden and improved survival rate. The properties of TS as a novel CAXII inhibitor have also been evaluated by CAXII activity assay, pHi, pHe and lactate level assay. Further RT-PCR and Caspase-3 activity analyses also revealed the positive regulating effects of TS on E2F1,3/Caspase-3 axis in TNBC cells cultured in 2D or 3D systems. The findings indicate that TS suppresses TNBC progression as a potential novel CAXII inhibitor in preclinical experiments, which warrants further investigation on its therapeutic implications.

show abstract

“…A larger proportion of younger women is reported in TNBC than older breast cancer patients [3,4]. The incidence of breast cancer in young patients has increased in recent years, worldwide [5]. In The United States, about 11% of breast cancer patients are between the ages of 35 and 45, and in Asia are 9.5-12%.…”

Section: Introductionmentioning

confidence: 99%

“…The proliferation inhibition rate was calculated following the formula as: inhibition rate = (1-Absorbance of treated sample /Absorbance of control Experimental protocols were approved by the Beijing University of TCM Institutional Animal care and Use Committee (No.104195489042) and adhered to the NIH Guide for the Care and Use of Laboratory Animals. A freshly prepared mixture (50 mL complete culture medium, 5×105 MDA-MD-231 Luc , 50 mL Corning Matrigel Matrix HC, Phenol Red-free, and LDEV-free) was directly injected into lower right…”

mentioning

confidence: 99%

Tiliroside suppresses Triple-negative breast cancer as a multifunctional CAXII inhibitor

Han¹,

Yang

Lü³

et al. 2022

Preprint

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor prognosis, early recurrence, and the lack of durable chemotherapy responses and specific targeted treatments. In this preclinical study, we examines Tiliroside (TS, C30H26O13), as one of the major compounds of Tribulus terrestris L. which has been used as alternative therapy in clinic practice of breast cancer treatment, for its therapeutic use in TNBC. The association between CAXII expression level and survival probability of TNBC patients, and the difference of CAXII expression level between TNBC and normal samples were evaluated by using public databases. To determine the anticancer efficacy of TS on TNBC cells, cell proliferation, wound healing, cell invasion, and 3D spheroid formation assays were performed and excellent anticancer activities of TS were displayed. Mouse models further demonstrate that TS significantly reduces the tumor burden and improves survival rate. The properties of TS as a novel CAXII inhibitor have also been evaluated by CAXII activity assay, pHi, pHe and lactate level assay. Further RT-PCR and Caspase-3 activity analyses also revealed the positive regulating effects of TS on E2F1,3/Caspase-3 axis in TNBC cells cultured in 2D or 3D systems. The findings indicate that TS suppresses TNBC progression as a potential novel CAXII inhibitor in preclinical experiments, which warrants further investigation on its therapeutic implications.

show abstract

A novel star-shaped trinuclear platinum(ii) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism

Abstract: Polynuclear platinum(II) complexes represent a class of great prospective Pt-based antitumor drugs that may expand the antitumor spectrum and overcome the clinical problems of drug resistance and side effects of...

Cited by 6 publications

References 63 publications

Two novel silver(I) phenanthroline derivative complexes induce G2/M phase cycle arrest and apoptosis of MDA‐MB‐231 cancer cells by multiple mechanisms

Two novel silver(I) phenanthroline derivative complexes induce G2/M phase cycle arrest and apoptosis of MDA‐MB‐231 cancer cells by multiple mechanisms

Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor

Tiliroside suppresses Triple-negative breast cancer as a multifunctional CAXII inhibitor

Contact Info

Product

Resources

About